KDR and posterior cortical atrophy: It has been suggested based on studies in PCa cell models that high-risk PCa patients, having tumors expressing low miR-221 microRNA and elevated VEGFR2 (i.e., vascular epithelial growth factor receptor 2, an miR-221 target), may benefit from initial anti-angiogenic therapy entailing VEGFR2 inhibition with a tyrosine kinase inhibitor, e.g., sunitinib, followed by immune checkpoint inhibition [63].